Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Biogen Spine Disease Drug Sales Strong in First Quarter Since Commercial Launch

Biogen Spine Disease Drug Sales Strong in First Quarter Since Commercial Launch

Biogen adjusted profit rose in the first quarter on a small increase in total revenue. Sales of the biotech company's multiple sclerosis drugs remain flat.

Biogen Hopes New Spine Drug Data Convinces Insurers to Loosen Patient Access, Boost Sales

Biogen Hopes New Spine Drug Data Convinces Insurers to Loosen Patient Access, Boost Sales

When Biogen reports first-quarter earnings Tuesday, investors will be looking to see if Spinraza sales match or exceed $16 million consensus.

Biomarin Rare Disease Drug Picks Up European Endorsement Ahead of FDA Action

Biomarin Rare Disease Drug Picks Up European Endorsement Ahead of FDA Action

If approved, Brineura will be the first and only treatment for CLN2 disease, a form of Batten disease.

TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market

TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market

Postmenopausal women already have a broad menu of locally administered estrogen therapy products to treat vulvar and vaginal atrophy.

XBiotech Leaves European Meeting 'Disappointed' Over Colon Cancer Drug Rejection

XBiotech Leaves European Meeting 'Disappointed' Over Colon Cancer Drug Rejection

XBiotech's efforts to shade Xilonix's clinical failings amounted to little more than hand waving when it mattered most. European regulators at the oral explanation meeting on Thursday were not fooled.